10 Stocks Lead Monday’s Charge Amid Market Bloodbath

2. TG Therapeutics Inc. (NASDAQ:TGTX)

TG Therapeutics surged by 14.39 percent on Monday to close at $34.42 apiece as investors cheered news of impressive earnings performance last year.

In its latest earnings report, TGTX said it swung to a net income of $23.3 million in the last quarter of 2024 from a net loss of $14.4 million in the same period a year earlier while net income in full-year 2024 surged by 84.5 percent to $23.38 million from $12.67 million.

Revenues for the quarter expanded by 146 percent to $108.18 million from $43.97 million, while revenues for the full year grew 41 percent to $329 million from $233.7 million.

For this year, TGTX is targeting revenues to end at $540 million, with $525 million expected to be owed to its BRIUMVI treatment.

Operating expense is also expected to hit $300 million, excluding non-cash compensation.